WntResearch continues to the next step in the phase 2 study NeoFox with the highest evaluated dose of Foxy-5
WntResearch announces today that the company, after a very fast patient recruitment, has been able to determine that the highest evaluated dose (8 mg/kg) of the drug candidate Foxy-5 will be used in the next step of the proof of concept study NeoFox. Approximately 80 patients with colon cancer will be treated in the second part of the study and an initial efficacy analysis is planned as early as the end of 2024.Previously reported ad hoc observations in patients with colon cancer indicate that the company's drug candidate Foxy-5 has a tumor-inhibiting effect already after three weeks of